Deals of the week: Zhejiang Dian Diagnostics, ACT Genomics, Cerus Corporation, Harmony Biopharm

12 May 2016 (Last Updated May 12th, 2016 18:30)

Zhejiang Dian Diagnostics, a provider of medical diagnostic solutions, has issued bonds through a private placement.

Zhejiang Dian Diagnostics, a provider of medical diagnostic solutions, has issued bonds through a private placement.

The bonds, due in 2026, will raise gross proceeds of up to CNY800m ($123m), which will be used to supplement circulating funds.

To further expand its footprint in Asia Pacific countries, ACT Genomics, an integrated cancer molecular information company, has raised $12.5m in series B round of funding.

Hotung Group and CDIB Capital Management Corporation led the funding, while the existing investors including Eminent II Venture Capital, Hua Nan Venture Capital, President International Development Corporation and UMC Capital also participated in the round.

ACT Genomics, which provides comprehensive genomic profiling assays and molecular information, will use the proceeds to strengthen its commercial channels, which will drive further global expansion.

The company has entered the Asia Pacific region earlier this year.

Cerus Corporation has proposed it will raise up to $70m in a public offering of shares. Cerus is a biomedical products company specialising in the field of blood transfusion safety.

The gross proceeds from the offering will be used by the company for general and administrative expenses and working capital.

Cooley LLP is the legal advisor for the offering, while Cantor Fitzgerald & Co. is the placement agent.

Harmony Biopharm has formed a joint venture with Tonghua Dongbao Pharmaceutical and Shanghai Dongbao Biological Pharmaceutical (Dongbao) to obtain regulatory approval for Dance 501, an inhaled insulin product to treat diabetes, in China.

"If Dance 501 gets approved in China, the JV, which is formed with an initial capitalisation of $11m, will further focus on its commercialisation."

Hong Kong-based Harmony Biopharm has licensed Dance 501, which is being developed by Dance Biopharm, for development and commercialisation in the Asia Pacific market.

If Dance 501 gets approved in China, the JV, which is formed with an initial capitalisation of $11m, will further focus on its commercialisation.

Tonghua Dongbao Pharmaceutical and Shanghai Dongbao Biological Pharmaceutical are the subsidiaries of Chinese conglomerate Dongbao Enterprise Group focused on producing and manufacturing insulin.

ReWalk Robotics, manufacturer of wearable robotic exoskeletons for individuals with spinal cord injuries, has announced a public offering of its common stock.

The company will raise gross proceeds of up to $25m, which will be used for general corporate purposes and R&D expenditures for product development.

Piper Jaffray & Co, Goldfarb Seligman & Co, and White & Case LLP are the legal advisors for the offering.